Genmab — April 2019
-
-
-
SGEN had quarterly earnings yesterday and said a few words about Tisotumab. Nothing we don't know yet I think. transcript: https://seekingalpha.com/article/4256999-seattle-genetics-inc-sgen-ceo-clay-siegall-q1-2019-results-earnings-call-transcript?part=single
-
Tisotumab vedotin or TV is and ADC that we are developing in partnership with Genmab. We are conducting a pivotal Phase 2 single-arm single-agent trial for women with recurrent or metastatic cervical cancer which has recently completed enrollment and is designed to support a regular submission under the FDA's accelerated approval mechanism.
-
The primary endpoint of this trial is confirmed objective response rate by independent review. Updated data from the Phase 1 trial were recently reported at the Society of Gynecologic Oncology annual meeting showing a 22% confirmed objective response rate by independent review with a median duration of response of six months.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind